# Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia

> **NCT02317159** · PHASE4 · UNKNOWN · sponsor: **Cttq** · enrollment: 90 (estimated)

## Conditions studied

- Chronic Myeloid Leukemia

## Interventions

- **DRUG:** Imatinib

## Key facts

- **NCT ID:** NCT02317159
- **Lead sponsor:** Cttq
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-02
- **Primary completion:** 2017-06
- **Final completion:** 2017-07
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2014-12-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02317159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02317159, "Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02317159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*